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Reactive multi-target ‘fragment drugs’ represent critical components of current
tuberculosis regimens. These compounds, such as pyrazinamide, are old synthetic
antimycobacterials that are activated inside Mycobacterium tuberculosis bacilli and
are smaller than the usual drug-like, single-target molecules. Based on the success
of small ‘dirty’ drugs in the chemotherapy of tuberculosis, we suggested previously
that fragment-based whole cell screens should be introduced in our current
antimycobacterial drug discovery efforts. Here, we carried out such a screen and
characterized bactericidal activity, selectivity and spectrum of hits we obtained. A library
of 1725 fragments was tested at a single concentration for growth inhibitory activity
against M. bovis BCG as screening strain and 38 of 116 primary hits were confirmed
in dose response analyses to be active against virulent M. tuberculosis. Bacterial
kill experiments showed that most hits displayed bactericidal activity at their minimal
inhibitory concentration. Cytotoxicity assays established that a large proportion of
hits displayed a favorable selectivity index for mammalian cells. Importantly, one third
of M. tuberculosis active fragments were also active against M. abscessus and
M. avium, two emerging non-tuberculous mycobacterial (NTM) pathogens, opening
the opportunity to develop broad spectrum antimycobacterials. Activity determination
against Gram positive (Staphylococcus aureus) and Gram negative (Escherichia coli,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa) bacteria,
as well as fungi (Candida albicans, Cryptococcus neoformans) showed only a small
overlap indicating a generally narrow spectrum of these novel antimicrobial hits for
mycobacteria. In conclusion, we carried out the first fragment-based whole cell
screen against bacteria and identified a substantial number of hits with excellent
physicochemical properties and dual activity against M. tuberculosis and NTM
pathogens. These hits will now be evaluated in animal models of mycobacterial infection
to determine whether any of them can be moved forward as a new antimycobacterial
fragment drug candidate.
Keywords: fragments, poly-pharmacology, tuberculosis, NTM, M. abscessus, M. avium
Abbreviations: CFU, colony forming units; NTM, non-tuberculous mycobacteria.
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INTRODUCTION
Mycobacterium tuberculosis remains the most deadly bacterial
pathogen globally and acquired resistance to current
antimycobacterials threatens global tuberculosis control
efforts (WHO, 2015). In addition to the tuberculosis pandemic,
new mycobacterial diseases are emerging. The number of
infections with intrinsically resistant environmental NTM such
as M. abscessus and M. avium are increasing in both developing
and developed countries. While prolonged chemotherapies are
required for treating M. avium infections, lung disease caused
by M. abscessus is considered incurable (Griffith et al., 2007;
Nessar et al., 2012; Aksamit et al., 2014; Park and Olivier, 2015).
Hence, there is an urgent medical need for new drugs with new
mechanisms of action – and with a broad antimycobacterial
spectrum of activity.
Current drug discovery strategies are largely based on Paul
Ehrlich’s magic bullet ‘one drug–one target’ concept. After a
decade of high throughput screening against isolated biochemical
targets the antimycobacterial discovery field largely moved
back to phenotypic whole cell screens to identify compounds
with antimicrobial activity first, then deconvolute the target
via selection of spontaneous resistance mutants and whole
genome sequencing. This strategic shift is due to the large
scale failure of target-based approaches. It turned out that the
double membrane-containing mycobacterial cell envelope is a
formidable permeability barrier. Enzyme inhibitors identified on
isolated targets often do not penetrate this mycobacterial fortress
(Payne et al., 2007; Barry et al., 2009; Gwynn et al., 2010). The low
permeability of the mycobacterial cell envelope also affects the
productivity of phenotypic whole cell screens which use the same
standard pharmaceutical chemical libraries employed for target-
based screens. Screening those drug-like, rule-of-five compliant
(Lipinski, 2000) archives has resulted in very low hit rates (Barry
et al., 2009; Campbell, 2011).
Interestingly, critical components of anti-tuberculosis
regimens, including the key sterilizing first line drug
pyrazinamide, are ‘dirty fragments’: they hit multiple targets,
i.e., they are ‘dirty,’ and their molecular weights are in the range
of 100–300 g/mol, i.e., they are ‘fragments.’ In addition, these
drugs are metabolized inside the tubercle bacillus. Only then,
after being ‘activated,’ they exert their antimicrobial activity
(Gopal and Dick, 2014). This type of mechanism of action
(poly-pharmacology), and physicochemical properties (‘extra’
small and reactive), are at odds with main stream antibacterial
drug discovery: attractive leads for medicinal chemistry should
inhibit a single target, have a decent size to bind a target with
high affinity, and should not be reactive to avoid side effects
(Dartois and Barry, 2010).
Fragments came to fame in modern drug discovery due to
a novel, ‘fragment-based’ screening approach against molecular
targets. This lead finding method makes use of very small, rule-
of-3 compliant (Congreve et al., 2003) molecules, with weak
binding affinities. Biophysical and structural biology methods are
employed to identify such weak binders to a particular target
and their modes of binding. The low affinity binders are then
extended or combined to develop tight, target-specific, high
affinity (nM) compounds. Fragments usually represent attractive
starting points for medicinal chemistry as they possess favorable
physicochemical and hence pharmacokinetic properties: they
are relatively small (<300 g/mol) and rather hydrophilic
(clogP < 3) and thus combine attractive water solubility with
good absorption and tissue distribution (Scott et al., 2012;
Hopkins et al., 2014).
Fragment drugs such as pyrazinamide which are also pro-
drugs, are among the most efficacious tuberculosis drugs.
Thus hitting multiple targets appears to be an attractive
property for antimycobacterials. Furthermore, fragments which
are small enough to bind multiple sites are more likely to
be accepted as substrate analogs as well and metabolized by
the bacterium, again a property that seems to make good
antimicrobials for tuberculosis. Being small and moderately
lipophilic is critical in achieving in vivo exposure and tissue
penetration, usually a major hurdle during lead optimization
(Dartois and Barry, 2013; Dartois, 2014). In the case of
mycobacteria, these physicochemical properties likely also have
a positive impact on cellular pharmacokinetics: fragments might
more easily penetrate the double membrane mycobacterial
cell envelope as porins, the channels spanning the outer
membrane, prefer small hydrophilic molecules. Thus, fragments
may have multiple advantages over larger molecules: favorable
absorption and systemic pharmacokinetic properties, favorable
tissue distribution and better bacterial uptake (Gopal and Dick,
2014).
Based on these considerations we decided to screen a fragment
library, typically only used for structure guided lead finding,
for hits showing whole cell activity against the tubercle bacillus.
We identified 38 fragments showing growth inhibitory activity
against M. tuberculosis. We characterized the hit molecules
regarding their bactericidal and cytotoxic activity. Furthermore,
the hits were profiled for their antimycobacterial, anti-Gram
positive/negative and their antifungal spectrum.
MATERIALS AND METHODS
Assembly of Fragment Library
Fragments were selected based on a computational filtration of
90,000 commercially available molecules from libraries supplied
by ChemBridge, Life Chemicals, Enamine, Bionet/Key Organics
and Maybridge. The rule-of-3 was applied (Congreve et al., 2003)
with additional selections up to molecular weight of 350 for dense
functionalities such as sulphonamides. The principle of positive
selection of desired hydrogen bonding groups and computational
clustering described by Baurin et al. (2004) were also applied
to ensure diverse proportional clusters representing a range of
polar and solubilising groups. Then a categorization of candidate
fragments was made with 0, 1, 2, or 3 H-bond donors, 0, 1,
or 2 positively charged nitrogen groups, and up to 1 negatively
charged group, the latter being a smaller set. Specific undesired
groups were removed such as non-aromatic N–N bonded
compounds (e.g., hydrazines), primary anilines, ureas/thioureas,
adamantanes, bromo or iodo containing compounds and more
than 2 chloro groups. From the approximately 6,000 remaining
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fragments, further prioritization was carried out with a focus
on structures which were not completely flat and had less
commonly encountered combinations of functionalities. This
resulted in a library of 1725 selected fragment compounds used
for whole cell screening described in this report. All fragments are
commercially available and the corresponding compound codes
of the hits identified in this work are given in Supplementary
Table S1.
Bacterial Strains, Cells, Culture
Conditions and Chemicals
Mycobacterium tuberculosis H37Rv (ATCC 27294), M. bovis BCG
(ATCC 35734), M. abscessus Bamboo (smooth morphotype)
and M. avium 11 liquid cultures were grown in Middlebrook
7H9 broth (BD Difco) supplemented with 0.5% albumin,
0.2% glucose, 0.085% sodium chloride, 0.5% glycerol, 0.05%
Tween80 as described previously (Lakshminarayana et al.,
2015). Escherichia coli (ATCC 25922), Klebsiella pneumoniae
(ATCC 700603, MDR), Acinetobacter baumannii (ATCC 19606),
Pseudomonas aeruginosa (ATCC 27853), Staphylococcus aureus
(ATCC 43300, MRSA), were cultured in cation-adjusted Mueller
Hinton broth at 37◦C overnight. Candida albicans (ATCC
90028), Cryptococcus neoformans (ATCC 208821) were cultured
for 3 days on Yeast Extract-Peptone Dextrose agar at 30◦C.
A yeast suspension of 106 to 5 × 106 cells/mL (as determined by
OD530, absorbance at 530 nm) was prepared from five colonies
and subsequently used for screening. HepG2 (ATCC HB.8065)
and A549 (ATCC CCL-185) cells were cultured at 37◦C with
5% CO2 atmosphere in DMEM media (Gibco) complemented
with 10% FBS heat-inactivated (Gibco), penicillin (100 U/mL,
Gibco) and streptomycin (100 µg/mL, Gibco). Red blood cells
were obtained from Interstate Blood Bank, Inc. Laboratory, USA.
Fragments were obtained from various chemical providers shown
in Supplementary Table S1. All experiments on M. tuberculosis
were conducted in a BSL-3 core facility following biosafety level 3
procedures.
Antimicrobial and Antifungal Assays
Antimycobacterial screens were carried out as follows. All
mycobacterial precultures were harvested at mid-log phase
and diluted to an OD600 (absorbance at 600 nm) of 0.05 in
complete 7H9 medium. M. bovis BCG bacterial suspensions
were then dispensed into 96-well plates (200 µL/well) with
a single concentration of 500 µM of fragment per well in
the primary screen. Plates were incubated for 5 days at
37◦C under shaking (100 rpm). Compounds causing growth
inhibition >80% as compared to untreated control in the
same plate were considered positive hits. Cells were manually
resuspended and OD was measured at 600 nm on M200Pro
plate reader (Tecan) (Murugasu-Oei and Dick, 2000; Gopal and
Dick, 2015; Lakshminarayana et al., 2015). Hits that were re-
confirmed in the same assay from re-ordered fresh powder
stock were then tested against M. tuberculosis in a dose-response
format (twofold serial dilution from a maximum concentration
of 500 µM). Active hits were subsequently tested against
M. abscessus and M. avium in a similar manner. M. abscessus
and M. avium containing 96-well plates were incubated for
3 and 5 days respectively at 37◦C under shaking (100 rpm).
Ten micromolar ciprofloxacin was used as a positive control
for M. tuberculosis and M. bovis BCG. Hundred micromolor
kanamycin was used as a positive control for M. abscessus
and M. avium. Bactericidal activity against M. bovis BCG was
determined by exposing approximately 106 CFU to MIC90
concentration for 5 days. CFU were then recovered on agar
plates for enumeration and compared to CFU recovered from
inoculum as described previously (Murugasu-Oei and Dick,
2000; Lakshminarayana et al., 2015). Fold-kill was calculated
as the reduction in CFU in treated samples as compared
to inoculum. All experiments were carried out two times
independently and mean values are shown. Standard deviations
were smaller than 20%.
Antimicrobial screening against gram positive and negative
bacteria as well as fungi was performed by the Community for
Antimicrobial Drug Discovery, University of Queensland, funded
by the Wellcome Trust (UK) and The University of Queensland
(Australia). A sample of an overnight culture of the respective
test bacterium was diluted 40-fold in fresh broth and incubated
at 37◦C for 1.5–3 h. The resultant mid-log phase cultures were
diluted (CFU/mL measured by OD600), then 45 µL was added
to each well of the compound containing plates, giving a cell
density of 5× 105 CFU/mL. The ten best compounds were tested
in a twofold serial dilution format at a maximum concentration
of 100 µM. All the plates were covered and incubated at 37◦C
for 18 h without shaking. Inhibition of bacterial growth was
determined measuring absorbance at 600 nm (OD600), using a
Tecan M1000 Pro monochromator plate reader. The percentage
FIGURE 1 | Screening cascade and hit characterization. (Upper part)
Screening cascade with associated number of hits. (Bottom part) Various
hits characterization activities. For details see Results.
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FIGURE 2 | Structure of the 10 most potent M. tuberculosis actives. See Table 1 for antibacterial, antifungal and cytotoxic activities.
of growth inhibition was calculated for each well, using the
negative control (media only) and positive control (bacteria
without inhibitors) on the same plate as references. Colistin and
Vancomycin were used as positive bacterial inhibitor standards
for Gram negative and Gram-positive bacteria, respectively, at
four concentrations including two above and two below the MIC
of the respective pathogens. All experiments were carried out
two times independently and mean values are shown. Standard
deviations were smaller than 20%.
Fungal stock suspensions described above were diluted
with Yeast Nitrogen Base broth to a final concentration of
2.5 × 103 CFU/mL. Then, 45 µL of the fungi suspension was
added to each well of the compound-containing plates. The ten
best compounds were tested in a twofold serial dilution format at
a maximum concentration of 100 µM. Plates were covered and
incubated at 35◦C for 24 h without shaking. Growth inhibition
of C. albicans was determined measuring absorbance at 530 nm
(OD530), while the growth inhibition of C. neoformans was
determined measuring the difference in absorbance between 600
and 570 nm (OD600-570), after the addition of resazurin (0.001%
final concentration) and incubation at 35◦C for additional 2 h.
The absorbance was measured using a Biotek Synergy HTX plate
reader. The percentage of growth inhibition was calculated for
each well, using the negative control (media only) and positive
control (fungi without inhibitors) on the same plate. Fluconazole
was used as a positive fungal inhibitor standard for C. albicans
and C. neoformans at four concentrations including two above
and two below the MIC. All experiments were carried out
two times independently and mean values are shown. Standard
deviations were smaller than 20%.
Cytotoxicity Assays
The MTS [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] reduction assay (Promega) was used according to
manufacturer’s guidelines to assess HepG2 or A549 cell viability
after exposure to a range of compound concentrations (twofold
serial dilution) (Riss et al., 2004). Absorbance was read with a
Tecan M200Pro plate reader at 570 nm. Hundred micromolor
of carbonyl cyanide m-chlorophenylhydrazone was used as a
cytotoxic positive control. Hemolytic activity was evaluated by
exposing 106 red blood cells to two-fold serial dilutions of
compounds in phosphate-buffered saline for 24 h. Red blood
cells were subsequently centrifuged at 1000 g for 10 min and
the supernatant was collected and homogenized by vortexing.
Absorbance was read at 540 nm. A Triton X-100 treated control
(2% Triton) was used to define 100% of hemoglobin release
(Dausset and Contu, 1967). All experiments were carried out
two times independently and mean values are shown. Standard
deviations were smaller than 20%.
Physico-Chemical Characterization of
Hits
Molecular properties of the fragment hits were calculated using
Molinspiration software1. Hydrogen bond donors are defined as
the total number of OH+NH groups. Hydrogen bond acceptors
are defined as the O + N count. Calculated LogP (cLogP) was
determined using the miLogP2.2 (November 2005) software from
Molinspiration. Topological Polar Surface Area (TPSA) (Ertl
et al., 2000) is defined as the sum of the surfaces of the polar atoms
in a molecule. Number of rotatable bonds (NROT) is defined
as the count of any single non-ring bond, bounded to a non-
hydrogen atom; NROT does not include amide bonds which are
considered non-rotatable.
RESULTS
Identification of Hits Active against
M. tuberculosis from a Fragment Library
A library of 1725 fragments was carefully selected out of a
collection of 90,000 commercially available fragments based on
their physicochemical and chemical properties (see Material
1http://www.molinspiration.com
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TABLE 2 | Physico-chemical properties of the 10 most potent
M. tuberculosis actives.
Fragments # MW HBD1 HBA2 clogP3 TPSA4 NROT5
1 221.3 1 3 2.54 37.8 3
2 263.7 0 4 3.30 47.9 2
3 243.3 0 4 1.98 56.3 2
4 320.9 2 3 4 37.2 5
5 235.3 0 2 1.88 20.3 1
6 175.2 0 3 0.04 57.9 1
7 259.7 0 4 3.35 40.0 2
8 210.7 2 4 1.76 54.5 1
9 214.3 1 2 2.41 28.7 1
10 175.2 3 3 1.52 54.7 1
MW, molecular weight; HBD, Hydrogen Bond Donor; HBA, Hydrogen
Bond Acceptor; 1Properties calculated using Molinspiration software
(www.molinspiration.com); HBD, OH + NH count. 2HBA, O + N count.
cLogP, partition coefficient between n-octanol and water log; 3cLogP, calculated
LogP (miLogP2.2 – November 2005). 4TPSA, Topological Polar Surface Area.
5NROT, number of rotatable bonds.
and Methods). We first screened the library against our
biosafety level 2 screening strain M. bovis BCG as a surrogate
for M. tuberculosis in order to identify hits with whole-cell
activity.
The screen was carried out using a single concentration of
500 µM of the test compounds. Growth inhibition of at least
80% was defined as cut-off which resulted in 184 primary hits
(11% hit rate). These hits were re-purchased as powders and
the compounds were re-tested in the same single point 500 µM
assay resulting in 116 confirmed hits (7% hit rate). For these
116 hits, growth inhibition dose response was measured against
M. tuberculosis and compounds with an MIC50 < 500 µM were
defined as whole cell actives, resulting in 38 hits (2% hit rate).
A cut-off of 500 µM was derived from the MIC50 of the anti-
tuberculosis fragment drug pyrazinamide which was selected as
a benchmark (Via et al., 2015). The screening cascade and hit
confirmation is depicted in Figure 1. Figure 2 and Table 1 show
the structures and the MIC50 of the most potent M. tuberculosis
active hits. Table 2 describes in detail their physicochemical
properties. The structures and activities of all 38 hits are shown
in Supplementary Table S1.
Bactericidal Activities and Cytotoxicity of
Hits
To determine the bactericidal activities of the hits we exposed
tubercle bacilli to MIC90 concentrations of the respective
compounds and counted CFU after 5 days of treatment. Table 1;
Supplementary Table S1 shows that more than half of the hits
reduced the number of CFU at least 100-fold showing that most
fragment hits displayed strong cidal activity. To evaluate in vitro
tolerability of the 38 M. tuberculosis actives we measured their
cytotoxicity against two mammalian cell lines as well as their
membrane toxicity using a red blood cell lysis assay. Table 1;
Supplementary Table S1 show that half of the hits showed
acceptable cytotoxic and hemolytic activity with a selectivity
index of more than 5.
FIGURE 3 | Activity of M. tuberculosis actives against M. avium and
M. abscessus. The diagram shows overlapping activity of 38 M. tuberculosis
hits against two non-tuberculous mycobacterial species.
Activity of M. tuberculosis Actives
against M. abscessus and M. avium
To establish the spectrum of activity of the 38 M. tuberculosis
active hits against other mycobacteria we measured their growth
inhibition activity against the fast growing M. abscessus and
the slow growing M. avium. Table 1; Supplementary Table S1
shows that two thirds of the M. tuberculosis actives were also
active against M. avium, while one third showed activity against
M. abscessus. Figure 3 shows that the 13 M. abscessus active hits
in fact represent a subset of the M. avium actives.
Activity of M. tuberculosis Actives
against Gram Positive and Gram
Negative Pathogens and Fungi
To examine whether the M. tuberculosis actives have a
mostly Mycobacterium-specific range of activity or tend to
display broad spectrum activity we determined their growth
inhibition against Gram positive (Staphylococcus aureus) and
negative (Escherichia coli, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa) bacteria, as well as
fungi (Candida albicans, Cryptococcus neoformans). Table 1;
Supplementary Table S1 show that only a small overlap was
observed indicating a generally narrow spectrum of the fragment
hits for mycobacteria.
DISCUSSION
Based on the success of pyrazinamide and other ‘dirty’ fragment
drugs in the treatment of tuberculosis patients, we previously
proposed that fragment-based whole cell screens, currently
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not part of mainstream drug discovery efforts, should be
included in antimycobacterial discovery activities (Gopal and
Dick, 2014). Here we carried out such a screen of 1725
compounds and identified 38 rule-of-3 compliant fragments (hit
rate 2%) with growth inhibitory activity against M. tuberculosis.
When compared to the hit rate of standard pharmaceutical
libraries (<0.5%; Campbell, 2011) this higher hit rate is
consistent with our expectation that small hydrophilic fragment
compounds should have favorable bacterial cell penetration
properties compared to larger and more hydrophobic molecules
(Gopal and Dick, 2014). Interestingly, most hits showed strong
mycobactericidal activity while a large fraction retained an
acceptable selectivity index for mammalian cells. All hits
displayed excellent physic-chemical properties and low molecular
weight but no particular structure-activity relationship could be
established. General pathogen spectrum profiling of the 38 anti-
tuberculosis hits against Gram positive and negative bacteria and
against fungi revealed a limited overlap suggesting that most of
the hits are rather Mycobacterium-specific.
Importantly, a substantial proportion of M. tuberculosis
hits also exhibited activity against NTM pathogens, specifically
M. abscessus and M. avium. New drugs to treat lung disease
caused by NTM represent an new urgent medical need as
M. avium causes a large number of infections requiring
prolonged treatments, and M. abscessus infections, although
smaller in number, are considered incurable (Griffith, 2011). The
identification of hits active against both M. tuberculosis and NTM
opens the opportunity to progress anti M. tuberculosis hits as
broad spectrum antimycobacterials.
The identified antimycobacterial fragment hits will now be
moved forward following two different strategies. Firstly, we will
ask whether we can ‘identify the next pyrazinamide,’ i.e., a new
antimycobacterial fragment drug. To explore this possibility we
will directly move hits into efficacy studies using mouse models
of mycobacterial infection, after selecting a subset of compounds
showing acceptable in vivo tolerability and pharmacokinetics.
If metabolic stability turns out to be an issue, minor chemical
modifications will be carried out to determine whether this
property can be improved without affecting potency. The
objective of this first strategy is to determine whether any of the
fragment hits can be moved more or less directly, i.e., without a
major lead optimization program, to preclinical development as
a fragment drug (Dick et al., 2007). In a second strategy we ask
whether we can use any of these rule-of-3 compliant fragment hits
to generate a more standard drug-like molecule, i.e., a rule-of-5
compliant, high affinity, high potency, single target compound.
Due to their fragment nature, all hits have excellent physico-
chemical properties and hence represent attractive starting points
for lead optimization campaigns.
In parallel to the two pronged drug discovery program, the
mechanism of action of the fragment hits will be determined.
It appears likely, due to their nature as promiscuous binders,
that the new antimycobacterials have multiple targets, i.e., that
they act as ‘dirty’ drugs. Furthermore, due to their potential
to act as enzyme substrates, and similarly to other anti-TB
fragment drugs such as isoniazid (INH), ethionamide (ETH),
para-amino salicylic acid (PAS) or pyrazinamide (PZA), it is
likely that a subset of the 38 fragment hits will be metabolized
and ‘activated’ by the bacilli, i.e., that they act as reactive ‘dirty’
drugs (Gopal and Dick, 2014). Dissecting the mechanisms of
action of existing tuberculosis fragment drugs resulted in the
identification of several novel targets and novel concepts of
antimicrobial action (Gopal and Dick, 2014). Hence we expect
that the mechanism of action studies of this collection of novel,
mostly bactericidal fragments may uncover novel antimicrobial
concepts.
CONCLUSION
We carried out the first fragment-based whole cell screen
against mycobacteria and identified a substantial number of
hits with excellent physicochemical properties which represent
a rich source for antimycobacterial drug discovery and chemical
biology projects.
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